By the Top Tier Newswire AI Desk · November 12, 2026 at 2:27 PM ET · reviewed against 3 wire stories
IMMUNITYBIO INC (IBRX) is down -9.37% in the latest session. Our newswire has captured 3 stories on IBRX across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ImmunityBio (IBRX) shares fell 9.37% to $6.05, marking the company's worst week in nearly two years. The decline followed the release of third-quarter financial results that showed a wider quarterly loss and missed revenue expectations, despite ongoing excitement regarding the sepsis potential of its drug Anktiva.
What Happened
ImmunityBio reported third-quarter 2026 financial results that included an adjusted earnings per share of negative $0.09, missing the estimate of negative $0.08. Sales came in at $48.841 million, falling short of the $59.250 million estimate. The company also disclosed findings from a survey of military members with non-muscle invasive bladder cancer. Founder Patrick Soon-Shiong stated that sepsis trials would begin soon in the United States and Europe, a development that continues to fuel retail interest in the stock's appeal to major pharmaceutical partners. The company is scheduled to participate in UK investor conferences during London Life Sciences Week 2026.
What The Data Shows
The stock opened at $6.62, a 0.7% gap down from the prior close of $6.67. It reached a session high of $6.64 at 7:20 AM ET before sliding to a session low of $6.02 at 2:20 PM ET. Volume reached 13.0 million shares, which is 1.1 times the three-month daily average. Over the last eight sessions, the stock has declined 16.1% from $7.95 to $6.67. The company printed 12 fresh 52-week lows on November 12, 2026, within a 52-week range of $1.95 to $12.43. Fundamentals show a market cap of $7.2 billion, with trailing twelve-month revenue up 121.2% and an EPS of negative $1.08. Recent insider activity includes two sales totaling $1.1 million, while congressional disclosures show two small buys by Lisa McClain in late September.
What To Watch
Investors will monitor the upcoming London Life Sciences Week 2026 conferences for further updates on the company's regulatory milestones and partnership discussions.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IBRX · Nov 12 session (5-min) · -7.80% vs prior close · updated 8:52 PM ETAI sentiment, last 36h · averaged over 3 stories · 57/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
1d agoStocktwits NewsBULLISH 58General
CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?
Sellas director Katherine Bach Kalin's purchased shares would be worth nearly $534,000 if retained, representing a 430% paper gain.
1d agoStocktwits NewsBULLISH 58Product/PR
IBRX Stock Eyes Worst Week In Nearly 2 Years — But Anktiva’s Sepsis Trial Potential Fuels Retail Bets On Big Pharma Appeal
Founder Patrick Soon-Shiong said sepsis trials would begin soon in the U.S. and Europe.
2d agoThe FlyBULLISH 56Product/PR
ImmunityBio announces findings from survey of military members with NMIBC
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →